Latest Profit Guidance News

IVE Group has raised its FY25 underlying NPAT guidance to approximately $52 million, driven by margin expansion despite a slight revenue dip. The company also outlined ambitious growth plans targeting $1.25 billion in revenue by 2030, focusing on diversified, sustainable marketing solutions.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Powerhouse Ventures Limited has issued its first-ever cash profit guidance for FY25, signalling a pivotal shift towards self-sustaining operations backed by strong corporate advisory and treasury performances.

AFT Pharmaceuticals has reported record revenue of NZD 208 million for FY25, driven by strong Australasian sales and a recovery in Asia and international markets. The company is targeting NZD 300 million in revenue by FY27, supported by an expanded R&D pipeline and ongoing geographic diversification.

Monash IVF Group has lowered its full-year profit guidance for FY2025 to $27.5 million, citing weaker market conditions and ongoing impacts from a recent operational incident in Brisbane. The company remains cautious as it monitors patient trends and legal costs.

TechnologyOne has reported record half-year results, boosting full-year profit growth guidance to 13%–17%, driven by its pioneering SaaS+ ERP platform and strategic expansion.

Judo Capital Holdings clarifies its recent Q3 financial disclosures, affirming compliance with ASX rules while highlighting FY26 profit guidance as material information.

AUB Group Limited has upgraded its FY25 underlying net profit guidance to the upper end of its previously announced range, buoyed by favourable trading conditions and strategic FX hedging.

Locality Planning Energy Holdings Ltd (ASX: LPE) reports a cashflow positive nine months to March 2025, confirms no material impact from Cyclone Alfred, and announces key board appointments to support growth.

Harmoney has raised its FY25 cash NPAT guidance to $5.5 million and announced an on-market share buy-back, setting the stage for accelerated loan book growth and improved returns in FY26.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.